vs
Cue Biopharma, Inc.（CUE）与Finward Bancorp（FNWD）财务数据对比。点击上方公司名可切换其他公司
Cue Biopharma, Inc.的季度营收约是Finward Bancorp的1.3倍（$21.9M vs $16.5M），Finward Bancorp净利率更高（12.0% vs 7.2%，领先4.8%），Cue Biopharma, Inc.同比增速更快（1292.3% vs 1.1%），过去两年Cue Biopharma, Inc.的营收复合增速更高（257.5% vs -19.1%）
Cue Biopharma是一家临床阶段生物技术企业，专注于开发针对癌症、自身免疫性疾病和炎症疾病的新型靶向免疫疗法，其专有平台可精准调节T细胞活性，主要业务覆盖北美地区，与全球药企合作推进核心候选产品的临床试验。
Finward Bancorp是一家总部位于美国的区域性银行控股公司，主要面向本土运营区域内的个人消费者与中小企业，提供储蓄账户、各类贷款、商业融资及财富管理等零售与商业金融服务。
CUE vs FNWD — 直观对比
营收规模更大
CUE
是对方的1.3倍
$16.5M
营收增速更快
CUE
高出1291.2%
1.1%
净利率更高
FNWD
高出4.8%
7.2%
两年增速更快
CUE
近两年复合增速
-19.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $21.9M | $16.5M |
| 净利润 | $1.6M | $2.0M |
| 毛利率 | — | — |
| 营业利润率 | 9.0% | 11.0% |
| 净利率 | 7.2% | 12.0% |
| 营收同比 | 1292.3% | 1.1% |
| 净利润同比 | 116.7% | -5.6% |
| 每股收益（稀释后） | $0.05 | $0.46 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CUEFNWD
| Q4 25 | $21.9M | $16.5M | ||
| Q3 25 | $2.1M | $17.4M | ||
| Q2 25 | $3.0M | $16.6M | ||
| Q1 25 | $421.0K | $15.5M | ||
| Q4 24 | $1.6M | $16.3M | ||
| Q3 24 | $3.3M | $14.9M | ||
| Q2 24 | $2.7M | $14.6M | ||
| Q1 24 | $1.7M | $25.3M |
净利润CUEFNWD
| Q4 25 | $1.6M | $2.0M | ||
| Q3 25 | $-7.4M | $3.5M | ||
| Q2 25 | $-8.5M | $2.2M | ||
| Q1 25 | $-12.3M | $455.0K | ||
| Q4 24 | — | $2.1M | ||
| Q3 24 | $-8.7M | $606.0K | ||
| Q2 24 | $-10.2M | $143.0K | ||
| Q1 24 | $-12.3M | $9.3M |
营业利润率CUEFNWD
| Q4 25 | 9.0% | 11.0% | ||
| Q3 25 | -353.4% | 20.5% | ||
| Q2 25 | -292.3% | 12.7% | ||
| Q1 25 | -2921.4% | 4.0% | ||
| Q4 24 | — | 16.3% | ||
| Q3 24 | -264.2% | 2.7% | ||
| Q2 24 | -390.6% | 0.9% | ||
| Q1 24 | -737.8% | 40.6% |
净利率CUEFNWD
| Q4 25 | 7.2% | 12.0% | ||
| Q3 25 | -346.6% | 20.1% | ||
| Q2 25 | -287.1% | 12.9% | ||
| Q1 25 | -2911.4% | 2.9% | ||
| Q4 24 | — | 12.9% | ||
| Q3 24 | -259.6% | 4.1% | ||
| Q2 24 | -382.7% | 1.0% | ||
| Q1 24 | -719.1% | 36.7% |
每股收益（稀释后）CUEFNWD
| Q4 25 | $0.05 | $0.46 | ||
| Q3 25 | $-0.07 | $0.81 | ||
| Q2 25 | $-0.09 | $0.50 | ||
| Q1 25 | $-0.17 | $0.11 | ||
| Q4 24 | — | $0.50 | ||
| Q3 24 | $-0.17 | $0.14 | ||
| Q2 24 | $-0.20 | $0.03 | ||
| Q1 24 | $-0.25 | $2.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $27.1M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $26.4M | $174.7M |
| 总资产 | $42.2M | $2.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CUEFNWD
| Q4 25 | $27.1M | — | ||
| Q3 25 | $11.7M | — | ||
| Q2 25 | $27.5M | — | ||
| Q1 25 | $13.1M | — | ||
| Q4 24 | $22.5M | — | ||
| Q3 24 | $32.4M | — | ||
| Q2 24 | $30.0M | — | ||
| Q1 24 | $41.0M | — |
总债务CUEFNWD
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.0M | — | ||
| Q2 24 | $2.0M | — | ||
| Q1 24 | $3.0M | — |
股东权益CUEFNWD
| Q4 25 | $26.4M | $174.7M | ||
| Q3 25 | $13.2M | $165.5M | ||
| Q2 25 | $18.2M | $154.3M | ||
| Q1 25 | $6.6M | $151.8M | ||
| Q4 24 | $17.5M | $151.4M | ||
| Q3 24 | $25.4M | $159.6M | ||
| Q2 24 | $21.6M | $148.6M | ||
| Q1 24 | $30.0M | $151.6M |
总资产CUEFNWD
| Q4 25 | $42.2M | $2.0B | ||
| Q3 25 | $31.6M | $2.1B | ||
| Q2 25 | $40.7M | $2.1B | ||
| Q1 25 | $22.3M | $2.0B | ||
| Q4 24 | $32.2M | $2.1B | ||
| Q3 24 | $44.8M | $2.1B | ||
| Q2 24 | $42.3M | $2.1B | ||
| Q1 24 | $54.0M | $2.1B |
负债/权益比CUEFNWD
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.09× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.1M | $9.9M |
| 自由现金流经营现金流 - 资本支出 | — | $9.0M |
| 自由现金流率自由现金流/营收 | — | 54.8% |
| 资本支出强度资本支出/营收 | 0.0% | 5.2% |
| 现金转化率经营现金流/净利润 | -0.68× | 4.99× |
| 过去12个月自由现金流最近4个季度 | — | $10.6M |
8季度趋势，按日历期对齐
经营现金流CUEFNWD
| Q4 25 | $-1.1M | $9.9M | ||
| Q3 25 | $-9.0M | $1.2M | ||
| Q2 25 | $-3.4M | $4.8M | ||
| Q1 25 | $-8.2M | $-3.8M | ||
| Q4 24 | $-36.3M | $9.8M | ||
| Q3 24 | $-7.5M | $-3.7M | ||
| Q2 24 | $-10.0M | $2.8M | ||
| Q1 24 | $-9.8M | $-25.0K |
自由现金流CUEFNWD
| Q4 25 | — | $9.0M | ||
| Q3 25 | — | $1.0M | ||
| Q2 25 | $-3.4M | $4.5M | ||
| Q1 25 | $-8.3M | $-4.0M | ||
| Q4 24 | $-36.4M | $6.7M | ||
| Q3 24 | $-7.5M | $-4.2M | ||
| Q2 24 | $-10.0M | $1.1M | ||
| Q1 24 | $-9.8M | $-736.0K |
自由现金流率CUEFNWD
| Q4 25 | — | 54.8% | ||
| Q3 25 | — | 6.0% | ||
| Q2 25 | -116.5% | 27.0% | ||
| Q1 25 | -1976.7% | -25.7% | ||
| Q4 24 | -2309.3% | 41.2% | ||
| Q3 24 | -225.7% | -28.5% | ||
| Q2 24 | -376.2% | 7.6% | ||
| Q1 24 | -573.0% | -2.9% |
资本支出强度CUEFNWD
| Q4 25 | 0.0% | 5.2% | ||
| Q3 25 | 0.0% | 0.9% | ||
| Q2 25 | 0.9% | 1.7% | ||
| Q1 25 | 35.6% | 1.2% | ||
| Q4 24 | 4.2% | 18.8% | ||
| Q3 24 | 0.0% | 3.4% | ||
| Q2 24 | 0.4% | 11.2% | ||
| Q1 24 | 3.2% | 2.8% |
现金转化率CUEFNWD
| Q4 25 | -0.68× | 4.99× | ||
| Q3 25 | — | 0.34× | ||
| Q2 25 | — | 2.22× | ||
| Q1 25 | — | -8.37× | ||
| Q4 24 | — | 4.66× | ||
| Q3 24 | — | -6.15× | ||
| Q2 24 | — | 19.23× | ||
| Q1 24 | — | -0.00× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
FNWD
暂无分部数据
